IDYA SVP Snyder granted 130,000 stock options

IDEAYA Biosciences SVP and General Counsel Douglas B. Snyder reported routine equity awards and employee share purchases.

Rhea-AI Filing Summary

IDEAYA Biosciences SVP and General Counsel Douglas B. Snyder reported routine equity awards and employee share purchases. On 05/30/2025 and 11/28/2025, he acquired 1,039 and 1,041 shares of common stock, respectively, at $16.9065 per share under the company’s Employee Stock Purchase Plan, bringing his directly held common stock to 2,080 shares.

On 01/30/2026, he received a stock option for 130,000 shares of common stock at an exercise price of $32.19. The option vests 25% on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years until fully vested on the fourth anniversary.

Insider Trade Summary

Grant/Award: 132,080 shares

Grant/Award 3 txns

Insider Snyder Douglas B.

Role SVP, General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	130,000	$0.00	$0.00
Grant/Award	Common Stock	1,041	$16.9065	$18K
Grant/Award	Common Stock	1,039	$16.9065	$18K

Holdings After Transaction: Stock Option (right to buy) — 130,000 contracts (Direct); Common Stock — 2,080 shares (Direct)

Footnotes (2)

1. F1. The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
2. F2. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IDYA SVP Douglas B. Snyder report?

Douglas B. Snyder reported acquiring common shares through an Employee Stock Purchase Plan and receiving a stock option grant. He bought 1,039 and 1,041 shares at $16.9065 and was granted options for 130,000 shares at a $32.19 exercise price.

How many IDEAYA (IDYA) shares does Douglas B. Snyder now hold directly?

After the reported transactions, Douglas B. Snyder directly holds 2,080 shares of IDEAYA Biosciences common stock. These shares were accumulated through employee stock purchase plan acquisitions reported on 05/30/2025 and 11/28/2025 at a purchase price of $16.9065 per share.

What are the terms of Douglas B. Snyder’s 130,000 IDYA stock option grant?

Snyder received a stock option to buy 130,000 IDEAYA common shares at a $32.19 exercise price. Twenty-five percent vest on the first anniversary of January 1, 2026, with the remainder vesting monthly so all options are fully vested on the fourth anniversary.

Were Snyder’s IDYA share purchases under an employee plan?

Yes. The reported common stock acquisitions were made under IDEAYA’s Employee Stock Purchase Plan. The filing notes these transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c), reflecting typical employee participation rather than open-market trading activity.

Is the 130,000 share IDYA option grant immediately exercisable?

No. The 130,000 share option grant is subject to time-based vesting. Twenty-five percent vest one year after January 1, 2026, and the remaining 75% vest in equal monthly installments, becoming fully vested and exercisable on the fourth anniversary of that vesting commencement date.

What is the expiration date of Snyder’s IDEAYA stock option grant?

The stock option granted to Douglas B. Snyder on 01/30/2026 for 130,000 IDEAYA shares expires on 01/30/2036. The option remains exercisable after vesting until that expiration date, subject to the company’s equity plan and any applicable employment-related conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 07:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snyder Douglas B.

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/30/2025		A(1)	V	1,039	A	$16.9065	1,039	D
Common Stock	11/28/2025		A(1)	V	1,041	A	$16.9065	2,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$32.19	01/30/2026		A		130,000		(2)	01/30/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

2. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Joshua Bleharski, as Attorney-in-Fact for Douglas B. Snyder	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.